Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas
Article in BMC Medicine (July 2023)
The most recent citing publication is shown below. View this citation on Dimensions.
Article in BMC Medicine (July 2023)